Antigen News and Research

RSS

First Edition: October 7, 2011

In today's headlines, reports about what the Institute of Medicine recommends in terms of the criteria and methods the Department of Health and Human Services should follow in developing the health law's essential benefits package.

7 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011

Free radical peroyxnitrite linked to failure of cytotoxic T-cells to eliminate tumors

Researchers at the Moffitt Cancer Center in Tampa, Fla., and colleagues have found that tumor cell resistance to a specific cancer immunotherapy designed to kill cancer cells can be blamed on a mechanism that involves the production of a free radical peroxynitrite (PNT) that causes resistance to therapeutic cancer-killing cells.

30 Sep 2011

Study identifies genetic mutations that affect immune response to measles vaccination

Researchers at Mayo Clinic are hacking the genetic code that controls the human response to disease vaccination, and they are using this new cipher to answer many of the deep-seated questions that plague vaccinology, including why patients respond so differently to identical vaccines and how to minimize the side effects to vaccination.

23 Sep 2011

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a way to image the spread of a particularly dangerous form of prostate cancer earlier than conventional imaging in use today, which may allow oncologists to find and treat these metastases more quickly and give patients a better chance at survival.

23 Sep 2011

Verax Biomedical receives FDA clearance for Platelet PGD test

A $30 test that takes fewer than 30 minutes to perform can prevent potentially deadly transfusions of bacterial contamination in platelets, according to a new study published in the peer-reviewed journal Transfusion. An early view of the study can be found at the journal's web site.

23 Sep 2011

Impotence after prostate cancer treatment

According to researchers patients undergoing treatment for prostate cancer could be at a risk of impotence. According to the new study, published in the Journal of the American Medical Association there may be a formula to help gauge those risks for three common types of treatment, including surgery and radiation.

21 Sep 2011

Prediction models may effectively identify erectile function after prostate cancer surgery

The development of prediction models that included variables such as pretreatment sexual function, patient characteristics and treatment factors appear to be effective at predicting erectile function 2 years after prostatectomy, external radiotherapy, or brachytherapy for prostate cancer, according to a study in the September 21 issue of JAMA.

21 Sep 2011

Tokai raises $23M in Series D3 financing

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that it has raised $23 million in a Series D3 financing.

20 Sep 2011

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive Phase 1 data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

19 Sep 2011

Generex issues update on Antigen Express spinout

Generex Biotechnology Corporation today provided an update on the status of the previously announced spinout of its wholly-owned subsidiary, Antigen Express, Inc..

16 Sep 2011

HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

The advanced development of a novel next-generation anthrax vaccine and a new type of anthrax antitoxin have received support through new contracts funded the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

16 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Seattle Genetics, Inc. and Oxford BioTherapeutics today announced that they have formed a strategic collaboration to jointly discover novel antibody-drug conjugates (ADCs) for cancer.

14 Sep 2011

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have made a landmark discovery in the battle against the rapid spread of aggressive cancers associated with PRL-3 oncoprotein.

9 Sep 2011

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

7 Sep 2011

IKEPLUS immunization completely eliminates TB bacteria from infected tissues

A potential vaccine against tuberculosis has been found to completely eliminate tuberculosis bacteria from infected tissues in some mice. The vaccine was created with a strain of bacteria that, due to the absence of a few genes, are unable to avoid its host's first-line immune response.

5 Sep 2011

Dendritic cells play central role in regulation of acetaminophen's toxicity

NYU School of Medicine researchers have discovered that dendritic cells in the liver have a protective role against the toxicity of acetaminophen, the widely used over-the-counter pain reliever and fever reducer for adults and children.

2 Sep 2011

Low-cost, portable technique can detect specific proteins in human blood

Blood tests are important diagnostic tools. They accurately tease-out vanishingly small concentrations of proteins and other molecules that help give a picture of overall health or signal the presence of specific diseases. Current testing procedures, however, are expensive and time-consuming, while sophisticated test equipment is bulky and difficult to transport.

2 Sep 2011

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Selecta Biosciences, Inc., a biopharmaceutical company developing an entirely new class of targeted vaccines and immunotherapies, today announced that Science Applications International Corporation (SAIC) has awarded Selecta a subcontract to develop a targeted synthetic vaccine particle product for malaria.

31 Aug 2011

Antigen News and Research

First Edition: October 7, 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Free radical peroyxnitrite linked to failure of cytotoxic T-cells to eliminate tumors

Study identifies genetic mutations that affect immune response to measles vaccination

UCLA's gene-based imaging system can accurately detect metastatic prostate cancers

Verax Biomedical receives FDA clearance for Platelet PGD test

Impotence after prostate cancer treatment

Prediction models may effectively identify erectile function after prostate cancer surgery

Tokai raises $23M in Series D3 financing

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

Generex issues update on Antigen Express spinout

HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

OBT, Seattle Genetics form strategic collaboration to discover novel ADCs for cancer

Landmark discovery in rapid spread of PRL-3 oncoprotein associated aggressive cancers

ImmunoCellular provides update on ICT-107 Phase II trial for glioblastoma multiforme

IKEPLUS immunization completely eliminates TB bacteria from infected tissues

Dendritic cells play central role in regulation of acetaminophen's toxicity

Low-cost, portable technique can detect specific proteins in human blood

SAIC awards Selecta a subcontract to develop synthetic nanoparticle vaccine for malaria

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News